利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.043 秒)

    Methods of Subtyping CRC and their Association with Treatment of Colon Cancer Patients with Oxaliplatin
    2.
    发明申请
    Methods of Subtyping CRC and their Association with Treatment of Colon Cancer Patients with Oxaliplatin 审中-公开
    方法分析CRC及其与治疗结肠癌患者与奥沙利铂的关系

    公开(公告)号：US20150366835A1

    公开(公告)日：2015-12-24

    申请号：US14738757

    申请日：2015-06-12

    申请人： NSABP Foundation, Inc.

    发明人： Katherine Lea Pogue-Geile ,  Nan Song ,  Soonmyung Paik

    IPC分类号： A61K31/282 ,  C12Q1/68

    CPC分类号： A61K31/282 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/158

    摘要： A gene expression signature identifies stage II colon cancer patients who will receive benefit from oxaliplatin. Oxaliplatin has been shown to lengthen the survival of colon cancer patients, when it is combined with 5-fluorouracil plus leucovorin (FULV) in NSABP clinical trial C-07. Gene expression signatures are used first to classify tumors with regard to their respective subtypes, enterocyte, TA, goblet, inflammatory and stem-like and detection of expression of the enterocyte subtype directs treatment of the patient with oxaliplatin.

    摘要翻译： 基因表达特征识别将获得奥沙利铂益处的II期结肠癌患者。 在NSABP临床试验C-07中，当与5-氟尿嘧啶+甲酰四氢叶酸（FULV）结合时，已经显示奥沙利铂可延长结肠癌患者的生存期。 首先使用基因表达特征对其各自的亚型，肠细胞，TA，杯状物，炎症和茎样样进行肿瘤分类，并检测肠细胞亚型的表达，指导患者用奥沙利铂治疗。

    PREDICTING RESPONSE TO CHEMOTHERAPY USING GENE EXPRESSION MARKERS
    3.
    发明申请
    PREDICTING RESPONSE TO CHEMOTHERAPY USING GENE EXPRESSION MARKERS 审中-公开
    使用基因表达标记对化疗的预测反应

    公开(公告)号：US20150079591A1

    公开(公告)日：2015-03-19

    申请号：US14490166

    申请日：2014-09-18

    申请人： Genomic Health, Inc. ,  NSABP Foundation, Inc.

    发明人： Joffre B. BAKER ,  John L. BRYANT ,  Soonmyung PAIK ,  Steven SHAK

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G16B20/00 ,  G16B25/00

    摘要： The present invention provides gene expression information useful for predicting whether a cancer patient is likely to have a beneficial response to treatment with chemotherapy, comprising measuring, in a biological sample comprising a breast tumor sample obtained from the patient, the expression levels of gene subsets to obtain a risk score associated with a likelihood of a beneficial response to chemotherapy, wherein the score comprises at least one of the following variables: (i) Recurrence Score, (ii) ESRI Group Score; (iii) Invasion Group Score; (iv) Proliferation Group Score; and (v) the expression level of the RNA transcript of at least one of MYBL2 and SCUBE2, or the corresponding expression product. The invention further comprises a molecular assay-based algorithm to calculate the likelihood that the patient will have a beneficial response to chemotherapy based on the risk score.

    摘要翻译： 本发明提供了可用于预测癌症患者是否可能对化疗治疗具有有益反应的基因表达信息，包括在包含从患者获得的乳腺肿瘤样品的生物样品中测量基因亚群的表达水平 获得与化疗有益反应的可能性相关的风险评分，其中所述评分包括以下变量中的至少一个：（i）复发评分，（ii）ESRI组评分; （iii）入侵小组得分; （iv）增殖组得分; 和（v）MYBL2和SCUBE2中的至少一种的RNA转录物的表达水平或相应的表达产物。 本发明还包括基于分子测定的算法来计算患者将基于风险评分对化学疗法有益的反应的可能性。

    GENE EXPRESSION MARKERS FOR PREDICTION OF PATIENT RESPONSE TO CHEMOTHERAPY
    5.
    发明申请
    GENE EXPRESSION MARKERS FOR PREDICTION OF PATIENT RESPONSE TO CHEMOTHERAPY 审中-公开
    用于预防患者对化疗反应的基因表达标记

    公开(公告)号：US20140206545A1

    公开(公告)日：2014-07-24

    申请号：US14132679

    申请日：2013-12-18

    申请人： NSABP FOUNDATION, INC. ,  GENOMIC HEALTH, INC.

    发明人： Joffre B. BAKER ,  Wayne COWENS ,  Kim M. CLARK-LANGONE ,  James HACKETT ,  Drew WATSON ,  Soonmyung PAIK

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/57419 ,  G01N2800/52

    摘要： The present invention relates to gene sets useful in assessing prognosis and/or predicting the response of cancer, e.g. colorectal cancer to chemotherapy. In addition, the invention relates to a clinically validated cancer test, e.g. colorectal test, for assessment of prognosis and/or prediction of patient response to chemotherapy, using expression analysis. The present invention accommodates the use of archived paraffin embedded biopsy material for assay of all markers in the relevant gene sets and therefore is compatible with the most widely available type of biopsy material.

    摘要翻译： 本发明涉及可用于评估预后和/或预测癌症反应的基因集，例如 结肠直肠癌化疗。 此外，本发明涉及临床验证的癌症测试，例如， 使用表达分析来评估预后和/或预测患者对化学疗法的反应。 本发明适用于存档石蜡包埋的活检材料用于相关基因组中所有标记物的测定，因此与最广泛可用的活检材料类型相容。